AMPH - Amphastar P - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Web URL: https://www.amphastar.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
AMPH Stock Overview
Market Cap in USD | 2,207m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2014-06-25 |
AMPH Stock Ratings
Growth 5y | 55.1 |
Fundamental | 93.3 |
Dividend | 0.00 |
Rel. Performance vs Sector | 0.69 |
Analysts | 4.00/5 |
Fair Price Momentum | 48.49 USD |
Fair Price DCF | 90.76 USD |
AMPH Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
AMPH Growth Ratios
Growth 12m | -1.00% |
Growth Correlation 12m | -51% |
Growth Correlation 3m | 83% |
CAGR 5y | 18.54% |
CAGR/Mean DD 5y | 1.11 |
Sharpe Ratio 12m | -0.14 |
Alpha vs SP500 12m | -26.35 |
Beta vs SP500 5y weekly | 0.68 |
ValueRay RSI | 43.77 |
Volatility GJR Garch 1y | 46.84% |
Price / SMA 50 | 1.88% |
Price / SMA 200 | 1.06% |
Current Volume | 167.7k |
Average Volume 20d | 356.9k |
External Links for AMPH Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of AMPH stocks?
As of October 05, 2024, the stock is trading at USD 46.72 with a total of 167,665 shares traded.
Over the past week, the price has changed by -2.71%, over one month by -0.38%, over three months by +23.76% and over the past year by -1.75%.
As of October 05, 2024, the stock is trading at USD 46.72 with a total of 167,665 shares traded.
Over the past week, the price has changed by -2.71%, over one month by -0.38%, over three months by +23.76% and over the past year by -1.75%.
What are the forecast for AMPH stock price target?
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 52.7 in October 2025. The stock is currently trading at 46.72. This means that the stock has a potential upside of +12.84%.
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 52.7 in October 2025. The stock is currently trading at 46.72. This means that the stock has a potential upside of +12.84%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 59.8 | 27.9 |
Analysts Target Price | 69 | 47.7 |
ValueRay Target Price | 52.7 | 12.8 |